[Belantamab mafodotin for treating relapsed or refractory multiple myeloma after 2 therapies](https://www.nice.org.uk/guidance/indevelopment/gid-ta11018). NICE technology appraisal guidance [ID5108]. Publication date to be confirmed

[Belantamab mafodotin for treating relapsed or refractory multiple myeloma after 4 or more therapies](https://www.nice.org.uk/guidance/indevelopment/gid-ta10568). NICE technology appraisal guidance [ID2701]. Publication date to be confirmed

[Belantamab mafodotin with bortezomib and dexamethasone for treating relapsed or refractory multiple myeloma after 1 or more treatments](https://www.nice.org.uk/guidance/indevelopment/gid-ta11203). NICE technology appraisal guidance [ID6212]. Publication date to be confirmed

[Daratumumab with bortezomib, lenalidomide and dexamethasone for untreated multiple myeloma when high-dose chemotherapy with stem cell transplant is unsuitable](https://www.nice.org.uk/guidance/indevelopment/gid-ta10726). NICE technology appraisal guidance [ID3843]. Publication date to be confirmed

[Elranatamab for treating relapsed or refractory multiple myeloma after 3 therapies](https://www.nice.org.uk/guidance/indevelopment/gid-ta10918). NICE technology appraisal guidance [ID4026]. Publication expected June 2024

[Isatuximab with pomalidomide and dexamethasone for treating relapsed and refractory multiple myeloma [Review of TA658]](https://www.nice.org.uk/guidance/indevelopment/gid-ta10979). NICE technology appraisal guidance [ID4067]. Publication expected April 2024

[Ixazomib citrate for maintenance treatment of untreated multiple myeloma in people who cannot have autologous stem cell transplant](https://www.nice.org.uk/guidance/indevelopment/gid-ta10589). NICE technology appraisal guidance [ID2706]. Publication date to be confirmed

[Selinexor with bortezomib and low-dose dexamethasone for treating relapsed refractory multiple myeloma](https://www.nice.org.uk/guidance/indevelopment/gid-ta10646). NICE technology appraisal guidance [ID3797]. Publication date to be confirmed

[Teclistamab for treating relapsed or refractory multiple myeloma after 3 treatments (Review of TA869)](https://www.nice.org.uk/guidance/indevelopment/gid-ta11418). NICE technology appraisal guidance [ID6333]. Publication expected September 2024

[Venetoclax with bortezomib and dexamethasone for treating relapsed or refractory multiple myeloma](https://www.nice.org.uk/guidance/indevelopment/gid-ta10502). NICE technology appraisal guidance [ID1565]. Publication date to be confirmed

[Venetoclax with dexamethasone for treating relapsed or refractory t(11;14)-positive multiple myeloma after lenalidomide and a proteasome inhibitor](https://www.nice.org.uk/guidance/indevelopment/gid-ta10926). NICE technology appraisal guidance [ID4040]. Publication date to be confirmed

## [1] TRUE